Why is Sotera Health stock sliding today?
Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.
How this was made
The 30-second read
Why it matters
The reaffirmed guidance and insider selling amplified the negative reaction, outweighing the earnings beat.
Market read
The earnings release caused a sharp intraday decline, but the broader market remained largely unaffected.
What to watch
Potential upside from the Nordion Cobalt‑60 segment if harvest schedules normalize later in the year.
Background
Sotera Health is a provider of sterilization and lab testing services; its Q3 results were released after a prior downgrade by JPMorgan.
Ticker impact
Sotera Health reported Q3 2026 earnings that beat estimates but gave a cautious outlook, causing a 9.5% share drop in afternoon trading.
likely further downside as investors digest the unchanged guidance and European demand softness.
The stock fell 9.5% on the day; management did not raise guidance despite strong results, and insider selling adds bearish pressure.
Market effects
Highlights ongoing demand softness in the European medical‑device sterilization market, potentially affecting peers.
Limited to U.S. investors; European markets may see similar sentiment pressure on related suppliers.
Minimal; the move is company‑specific and does not drive broader market indices.
Counterpoint
The earnings beat suggests underlying strength; the stock may be oversold and could rebound on a future guidance raise.
Key entities
- companySotera Health
Healthcare sterilization and lab testing firm (ticker SHC).
- analystJPMorgan
Downgraded Sotera to Underweight and set a $17 price target.




